For example, GLP-1R agonists can alleviate the IRI of various organs, improve the metabolic disorders in NAFLD and the endothelial dysfunction in Atherosclerosis, reduce the death of neurons in neurodegenerative diseases and the HA in PCOS, reduce the use of addictive substances, promote the bone formation in osteoporosis, delay the deterioration of renal function, regulate gut microbiota, and prolong graft survival (Figure 3). This evidence concerns the gene GLP1R and osteoporosis.